MT-601 T Cell Therapy for Relapsed Non-Hodgkin Lymphoma
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
['FUNDING_SBIR_2'] · MARKER THERAPEUTICS, INC. · NIH-11164733
This opportunity explores a new T cell therapy called MT-601 for people with Non-Hodgkin Lymphoma that has returned after previous treatments.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MARKER THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11164733 on ClinicalTrials.gov |
What this research studies
This therapy, MT-601, is a new type of immunotherapy that uses your own immune cells to fight cancer. We collect your T cells and train them to recognize six specific markers found on lymphoma cells, but not on healthy cells. These specially prepared T cells are then given back to you to target and destroy the cancer cells. The goal is to create a stronger and more lasting anti-tumor response while potentially reducing severe side effects seen with other T cell therapies.
Who could benefit from this research
Good fit: Ideal candidates are patients with Non-Hodgkin Lymphoma whose cancer has returned after receiving prior CAR T cell therapy or other treatments.
Not a fit: Patients whose Non-Hodgkin Lymphoma has not relapsed or who have not received prior CAR T cell therapy may not be suitable for this specific treatment approach.
Why it matters
Potential benefit: If successful, this therapy could offer a new treatment option for Non-Hodgkin Lymphoma patients who have relapsed after other T cell therapies, potentially leading to better outcomes and fewer side effects.
How similar studies have performed: While CAR T cell therapies have shown impressive results in NHL, this approach is novel in targeting multiple tumor antigens simultaneously to address relapse after CAR T therapy.
Where this research is happening
HOUSTON, UNITED STATES
- MARKER THERAPEUTICS, INC. — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VERA, JUAN FERNANDO — MARKER THERAPEUTICS, INC.
- Study coordinator: VERA, JUAN FERNANDO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.